Overview

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. - This research study involves the following drug(s): - Cemiplimab - Everolimus or Sirolimus - Prednisone
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Cemiplimab
Everolimus
Prednisone
Sirolimus